The buzz around Initial Public Offerings (IPOs) is always exciting, especially when it’s a company like Amanta Healthcare, a Gujarat-based pharmaceutical firm making waves in the sterile liquid products market. With its IPO opening for subscription on September 1, 2025, and closing on September 3, 2025, investors are eager to understand the Grey Market Premium (GMP) and what it signals about potential listing gains. As someone who’s been following the IPO market for a while, I’m here to break down everything you need to know about Amanta Healthcare’s IPO GMP in a way that’s easy to grasp, even if you’re new to investing. Let’s dive into the details, explore the company, and see if this IPO is worth your attention.
Table of Contents
What Is Amanta Healthcare and Its IPO About?
Amanta Healthcare Limited, founded in 1994 in Ahmedabad, is a well-established player in the pharmaceutical industry, specializing in sterile liquid products like Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs). These are fancy terms for things like IV fluids, eye drops, respiratory solutions, and irrigation fluids, all packaged using advanced technologies like Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). The company operates a massive WHO-GMP certified facility in Hariyala, Gujarat, spanning over 66,852 square meters, and serves both domestic and international markets, exporting to 19 countries.
The Amanta Healthcare IPO is a book-built issue aiming to raise ₹126 crores through a fresh issue of 1 crore equity shares, each with a face value of ₹10. The price band is set between ₹120 and ₹126 per share, with a minimum lot size of 119 shares, meaning retail investors need at least ₹14,994 to apply at the upper price band. The IPO opened on September 1, 2025, and will close on September 3, with allotment expected on September 4 and a tentative listing date of September 9, 2025, on BSE and NSE.
- Issue Size: ₹126 crores, entirely fresh issue of 1 crore shares.
- Price Band: ₹120–₹126 per share.
- Lot Size: 119 shares (₹14,994 for retail investors at upper band).
- Subscription Dates: September 1–3, 2025.
- Listing: BSE and NSE, tentative date September 9, 2025.
Understanding Grey Market Premium (GMP) and Its Significance
If you’re new to IPOs, you might be wondering what GMP is. Grey Market Premium is the price at which IPO shares trade in the unofficial, unregulated grey market before they officially list on stock exchanges. It’s like a sneak peek into how the market perceives the IPO’s demand and potential listing price. A positive GMP suggests investors expect the stock to list above the issue price, while a negative GMP could indicate lower demand.
For Amanta Healthcare, the GMP has been fluctuating but shows promise. As of August 31, 2025, reports indicate the GMP is around ₹25 per share. At the upper price band of ₹126, this suggests a potential listing price of approximately ₹151, which could mean a listing gain of about 19.84% or ₹2,975 per lot for retail investors. However, GMP is speculative and can change rapidly based on market sentiment, so it’s not a guaranteed predictor of listing performance.
- GMP as of August 31, 2025: ₹25 per share.
- Estimated Listing Price: ₹151 (₹126 + ₹25).
- Potential Gain: ~19.84% for retail investors.
- Caveat: GMP is volatile and not an official metric.
Financial Performance and Market Position
Before jumping into any IPO, it’s crucial to peek under the hood at the company’s financial health. Amanta Healthcare’s financials paint a mixed but improving picture. In FY25, the company reported a total income of ₹276.09 crores, a slight dip of 2% from ₹281.61 crores in FY24. However, its profit after tax (PAT) saw a massive jump of 189%, rising from ₹3.63 crores in FY24 to ₹10.5 crores in FY25. This turnaround from a small loss in FY23 shows Amanta is stabilizing and improving its margins, with an EBITDA margin exceeding 22% in FY25.
Amanta operates in a competitive space, going up against big names like Cipla, Sun Pharma, and Mankind Pharma, as well as smaller players like Denis Chem Lab. Its strength lies in its diversified portfolio across six therapeutic segments—fluid therapy, ophthalmics, respiratory care, irrigation solutions, diluents, and medical devices. With over 45 generic products and a strong export presence in 19 countries, Amanta’s balanced revenue mix (67% domestic, 33% exports in FY25) reduces risk from over-reliance on one market.
- Revenue (FY25): ₹276.09 crores (down 2% from FY24).
- Profit After Tax (FY25): ₹10.5 crores (up 189% from FY24).
- Market Reach: 320+ distributors in India, exports to 21 countries.
- Competitive Edge: WHO-GMP certified facility, diverse product portfolio.
Strengths and Risks of Investing in Amanta Healthcare IPO
Every investment comes with its pros and cons, and Amanta Healthcare is no exception. On the plus side, the company has a robust manufacturing setup with high capacity utilization (96% as of March 31, 2025), indicating strong demand. Its IPO proceeds will fund expansion, including new SteriPort and SVP manufacturing lines, which could drive future growth. Amanta’s global reach, with 113 product registrations across 19 countries, and adherence to strict regulatory standards like WHO-GMP, ISO, and country-specific certifications, make it a credible player in the pharma space.
However, there are risks to consider. The company operates in a highly competitive and fragmented market, which could pressure pricing and margins. Its high finance costs—62.6% of EBITDA in FY23, though improving—could strain cash flows if not managed. Additionally, Amanta is involved in material litigation, and an adverse outcome could impact its business. The IPO’s valuation, with a P/E ratio of 46.60x at the upper price band, is seen as steep by some analysts, suggesting it’s priced for perfection.
- Strengths:
- Advanced manufacturing with WHO-GMP and ISO certifications.
- Strong export presence in 19 countries.
- High capacity utilization and diversified portfolio.
- Risks:
- High competition from established and emerging players.
- Significant finance costs impacting cash flows.
- Steep valuation (P/E of 46.60x post-IPO).
- Pending legal proceedings.
Should You Invest in Amanta Healthcare IPO?
Deciding whether to invest in Amanta Healthcare’s IPO depends on your risk appetite and investment horizon. The GMP of ₹25 suggests a decent listing pop of around 19–20%, which could appeal to short-term investors chasing quick gains. However, GMP is speculative, and listing gains aren’t guaranteed. For long-term investors, Amanta’s improving profitability, diversified revenue streams, and planned capacity expansion make it a compelling story, especially in the growing pharmaceutical sector, where exports are projected to grow 6–8% in FY25.
That said, the high valuation and competitive pressures warrant caution. Analysts like Dilip Davda from Chittorgarh suggest the IPO is “exorbitantly priced” and recommend it only for well-informed or cash-surplus investors with a medium-term horizon. If you’re a retail investor, applying for the minimum lot could be a low-risk way to participate, but don’t go all-in without consulting a financial advisor and reviewing the Red Herring Prospectus (RHP).
- Who Should Invest:
- Aggressive investors seeking listing gains.
- Long-term investors with a 3–5 year horizon.
- Who Should Avoid:
- Risk-averse investors uncomfortable with high valuations.
- Those relying solely on GMP for decisions.
Frequently Asked Questions (FAQs)
1. What is the Amanta Healthcare IPO price band?
The price band is ₹120 to ₹126 per equity share, with a face value of ₹10.
2. When does the Amanta Healthcare IPO open and close?
It opens on September 1, 2025, and closes on September 3, 2025.
3. What is the lot size for retail investors?
The minimum lot size is 119 shares, requiring an investment of ₹14,994 at the upper price band.
4. What is the current GMP of Amanta Healthcare IPO?
As of August 31, 2025, the GMP is around ₹25 per share, indicating a potential listing price of ₹151 (19.84% gain).
5. When will the Amanta Healthcare IPO list?
The tentative listing date is September 9, 2025, on BSE and NSE.
6. How can I check the allotment status?
You can check the allotment status on the MUFG Intime India registrar portal (in.mpms.mufg.com) or BSE/NSE websites using your PAN, application number, or DP ID.
7. Is the Amanta Healthcare IPO a good investment?
It offers potential listing gains based on GMP, but the high valuation and competitive risks make it suitable for aggressive or long-term investors. Consult a financial advisor before applying.
Final Thoughts
The Amanta Healthcare IPO is an exciting opportunity in the pharmaceutical space, with its GMP signaling a healthy listing gain of around 19–20%. The company’s strong manufacturing capabilities, global reach, and improving financials make it a solid contender for long-term growth, but the high valuation and competitive landscape call for caution. Whether you’re a seasoned investor or just dipping your toes into IPOs, weigh the risks and rewards carefully. Keep an eye on the subscription status and GMP trends closer to the listing date, and always do your homework before investing. Happy investing!
Sources: